envelop
virus
gain
entri
host
cell
fuse
cellular
membran
step
requir
viru
replic
coronavirus
includ
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
infecti
bronchiti
viru
ibv
fuse
plasma
membran
use
receptormedi
endocytosi
fuse
endosom
depend
cell
tissu
type
viru
spike
protein
mediat
fusion
host
cell
membran
shown
previous
abl
kinas
inhibitor
imatinib
significantli
reduc
sarscov
merscov
viral
titer
prevent
endosom
entri
hiv
sar
mer
pseudotyp
virion
sarscov
merscov
classifi
virus
make
experiment
cellular
mechan
involv
infect
challeng
use
ibv
viru
model
studi
role
abl
kinas
activ
coronaviru
infect
found
imatinib
two
specif
abl
kinas
inhibitor
reduc
ibv
titer
block
first
round
viru
infect
addit
three
drug
prevent
ibv
sinduc
syncytia
format
prior
hemifus
step
result
indic
membran
fusion
viruscel
cellcel
block
presenc
abl
kinas
inhibitor
studi
effect
abl
kinas
inhibitor
ibv
use
identifi
host
cell
pathway
requir
coronaviru
infect
provid
insight
possibl
therapeut
target
treat
infect
current
well
newli
emerg
coronavirus
coronavirus
envelop
rna
virus
includ
caus
common
cold
well
highli
pathogen
sarscov
merscov
order
gain
entri
host
cell
envelop
virus
includ
coronavirus
fuse
cellular
membran
coronavirus
bind
cell
surfac
receptor
fuse
plasma
membran
endocytos
fuse
endosom
fusion
step
requir
order
viral
genom
deliv
host
cell
cytoplasm
replic
sar
mer
coronavirus
fuse
late
earli
endosom
respect
also
plasma
membran
viru
protein
mediat
fusion
viral
host
cell
membran
sinc
outbreak
sarscov
merscov
virus
studi
extens
order
understand
infect
pathogen
goal
identifi
therapeut
target
highthroughput
screen
identifi
abelson
abl
kinas
inhibitor
imatinib
inhibitor
sarscov
merscov
abl
kinas
nonreceptor
tyrosin
kinas
local
cytoplasm
two
abl
kinas
express
human
cell
involv
sever
cellular
process
rang
embryon
morphogenesi
mediat
viral
infect
imatinib
small
molecul
inhibitor
specif
design
target
abl
kinas
portion
bcrabl
protein
result
chromosom
transloc
caus
chronic
myeloid
leukemia
cml
previous
shown
imatinib
block
entri
pseudotyp
virion
contain
sarscov
merscov
protein
inhibit
sar
mer
coronaviru
entri
imatinib
implic
abl
kinas
activ
coronaviru
infect
report
group
demonstr
abl
kinas
involv
infect
sever
virus
strongli
suggest
abl
kinas
signal
pathway
promis
investig
develop
antivir
therapi
base
result
previou
report
hypothes
abl
kinas
activ
requir
entri
coronavirus
presum
viruscel
fusion
classif
sarscov
merscov
pathogen
sarscov
select
agent
present
barrier
experiment
method
perform
live
virus
addit
membran
composit
pseudotyp
virion
differ
true
virion
sinc
pseudotyp
virion
bud
plasma
membran
true
virion
bud
endoplasm
reticulumgolgi
intermedi
compart
could
lead
differ
viruscel
fusion
entri
mechan
import
evalu
effect
live
viru
system
advantag
find
coronaviru
use
model
infect
report
effect
imatinib
two
abl
kinas
inhibitor
ibv
infect
show
abl
kinas
inhibitor
interfer
first
round
ibv
infect
indic
inhibit
viruscel
fusion
addit
directli
demonstr
cellcel
fusion
syncytia
format
mediat
ibv
inhibit
imatinib
prior
hemifus
suggest
role
abl
kinas
viruscel
cellcel
fusion
event
ibv
excel
model
determin
mechan
abl
kinas
action
coronaviru
entri
order
find
new
target
therapeut
intervent
plasmid
pcaggssarscov
pcaggsvsv
g
previous
describ
rrfrr
furin
cleavag
site
pcr
amplifi
cdna
vector
contain
codonoptim
sequenc
ibv
nucleotid
flank
hindiii
xmai
site
pcr
amplifi
cdna
contain
codonoptim
sequenc
ibv
quikchang
mutagenesi
agil
genom
use
remov
hindiii
restrict
site
amplicon
ligat
togeth
full
code
sequenc
confirm
dideoxi
sequenc
antibodi
abl
kinas
inhibitor
mous
monoclon
antiibv
antibodi
recogn
lumen
domain
kind
gift
ellen
collisson
western
univers
health
scienc
rabbit
polyclon
antiibv
antibodi
cterminu
previous
describ
rabbit
polyclon
antibodi
sar
antisct
rabbit
antigfp
obtain
thermofish
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
tbst
incub
room
temperatur
h
goat
antirabbit
igg
licor
bioscienc
lincoln
ne
membran
wash
x
min
tbst
rins
tb
band
visual
use
licor
odyssey
clx
quantifi
use
imag
studio
softwar
densiti
three
ibv
band
correspond
measur
percent
band
calcul
total
treatment
condit
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
shown
previous
imatinib
lower
sarscov
merscov
titer
test
effect
imatinib
well
two
abl
kinas
inhibitor
ibv
infect
order
determin
whether
ibv
could
use
model
investig
abl
kinas
involv
coronaviru
infect
use
two
differ
type
inhibitor
order
determin
target
specif
well
mechan
inhibit
imatinib
competit
inhibitor
bind
near
atpbind
pocket
prevent
bind
atp
imatinib
bind
abl
kinas
close
inact
conform
bind
autoinhibitori
myristatebind
site
abl
kinas
lead
inactiv
activ
kinas
promot
close
conform
imatinib
sever
cellular
target
specif
inhibit
abl
kinas
treat
infect
cell
specif
inhibitor
allow
us
evalu
likelihood
abl
kinas
involv
coronaviru
infect
oppos
cellular
target
imatinib
vero
cell
infect
ibv
moi
absenc
presenc
three
inhibitor
supernat
harvest
h
postinfect
plaqu
assay
use
measur
viral
titer
sampl
result
experi
show
three
drug
significantli
decreas
viru
titer
imatinib
lower
viral
titer
compar
control
lower
titer
figur
next
determin
whether
decreas
titer
due
reduc
viru
product
infect
cell
result
fewer
cell
infect
indirect
immunofluoresc
microscopi
use
antibodi
ibv
protein
use
count
number
infect
cell
absenc
presenc
abl
kinas
inhibitor
observ
show
imatinib
reduc
number
cell
infect
decreas
number
infect
cell
compar
control
figur
result
demonstr
decreas
ibv
titer
due
decreas
number
cell
infect
inhibit
suggest
andor
specif
play
role
ibv
infect
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
previous
show
imatinib
prevent
entri
pseudotyp
virus
express
sarscov
merscov
protein
order
determin
ibv
block
entri
step
abl
kinas
inhibitor
infect
vero
cell
high
moi
durat
would
allow
one
round
infect
supernat
harvest
h
postinfect
ibv
titer
measur
use
plaqu
assay
result
experi
show
signific
decreas
viru
titer
ibvinfect
cell
treat
imatinib
compar
control
titer
reduc
imatinib
figur
also
observ
decreas
total
number
cell
infect
treatment
three
drug
figur
consid
decreas
number
cell
infect
could
due
decreas
viru
bind
host
cell
receptor
address
infect
vero
cell
high
moi
h
remov
imatinib
indic
time
point
postinfect
figur
cell
pretreat
dmso
imatinib
either
dmso
imatinib
present
infect
medium
adsorpt
pretreat
occur
adsorpt
occur
imatinib
revers
inhibitor
abl
kinas
observ
rapid
revers
effect
ibv
infect
remov
cell
cultur
medium
result
experi
show
imatinib
remov
cell
cultur
medium
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
ergolgi
intermedi
compart
protein
also
transport
cell
surfac
late
infect
protein
surfac
virion
mediat
viruscel
fusion
surfac
infect
cell
mediat
cellcel
fusion
result
syncytia
format
viral
protein
mediat
event
seem
like
viruscel
cellcel
fusion
may
use
cellular
mechan
due
difficulti
captur
individu
viruscel
fusion
event
analyz
cellcel
fusion
measur
syncytium
size
absenc
presenc
imatinib
vero
cell
infect
ibv
observ
syncytia
format
averag
nuclei
per
syncytium
figur
b
treatment
imatinib
result
statist
signific
reduct
nuclei
per
syncytium
averag
syncytium
size
reduc
nuclei
imatinib
respect
reduct
presenc
drug
figur
b
next
determin
whether
imatinib
inhibit
syncytia
format
induc
protein
alon
exogen
express
similar
infect
observ
format
syncytia
contain
averag
nuclei
vero
cell
transfect
plasmid
encod
ibv
figur
b
treat
ibv
stransfect
cell
abl
kinas
inhibitor
significantli
reduc
number
nuclei
per
syncytium
nuclei
imatinib
reduct
figur
b
sarscov
also
inhibit
imatinib
want
determin
whether
abl
kinas
inhibitor
interfer
fusion
induc
sarscov
end
also
test
effect
three
drug
syncytia
format
produc
sarscov
protein
vero
cell
transient
transfect
plasmid
encod
sarscov
number
nuclei
per
syncytium
reduc
imatinib
compar
number
nuclei
per
syncytium
untreat
cell
figur
averag
syncytium
size
induc
sarscov
much
smaller
induc
ibv
nuclei
nuclei
per
syncytium
respect
treatment
three
drug
reduc
averag
three
nuclei
per
syncytium
ibv
sarscov
note
treatment
abl
kinas
inhibitor
reduc
number
nuclei
per
syncytium
also
total
number
syncytia
quantifi
observ
syncytia
contain
greater
equal
three
nuclei
found
control
cell
routin
found
fewer
syncytia
drugtreat
sampl
addit
two
data
point
sarscov
imatinibtr
cell
due
fact
syncytia
found
one
replic
experi
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
treatment
imatinib
effect
total
number
cell
express
vsvg
transfect
control
plasmid
pcaggsvsvg
demonstr
effect
inhibitor
due
transfect
effici
data
shown
togeth
result
demonstr
imatinib
interfer
syncytia
format
mediat
protein
ibv
infect
protein
exogen
express
absenc
infect
fact
see
phenotyp
sarscov
ibv
reinforc
idea
ibv
use
model
coronaviru
studi
abl
kinas
involv
coronaviru
infect
mix
outer
membran
leaflet
hemifus
follow
inner
leaflet
mix
figur
ibv
stain
shown
use
ensur
coexpress
ibv
yfpgpi
hela
cell
observ
total
fusion
event
control
sampl
total
fusion
event
sampl
treat
wtih
imatinib
sampl
respect
hemifus
event
account
fusion
event
control
cell
cell
treat
imatinib
respect
figur
although
total
fusion
event
drugtreat
cell
reduc
expect
treatment
imatinib
show
signific
chang
percent
hemifus
event
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
compar
control
cell
figur
suggest
abl
kinas
inhibitor
block
initi
hemifus
step
result
demonstr
abl
kinas
inhibitor
interfer
cellcel
fusion
necessari
syncytia
format
provid
evid
drug
may
inhibit
viruscel
fusion
prevent
hemifus
first
step
membran
mix
consid
treatment
abl
kinas
inhibitor
could
affect
ibv
process
could
caus
block
cellcel
fusion
full
length
protein
undergo
two
cleavag
event
necessari
cellcel
fusion
take
place
first
occur
site
produc
two
fragment
second
cleavag
occur
site
result
exposur
fusion
peptid
strain
vero
cell
use
ibv
cleav
virion
exocytosi
provid
fusioncompet
viru
prior
host
cell
receptor
bind
exposur
fusion
peptid
shown
necessari
cellcel
fusion
syncytia
format
measur
amount
cleavag
product
treatment
imatinib
none
drug
treatment
decreas
rel
amount
figur
indic
ibv
protein
process
cleavag
affect
abl
kinas
inhibitor
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
demonstr
abl
kinas
inhibitor
imatinib
reduc
viral
titer
ibv
decreas
number
cell
infect
first
round
viru
infect
inhibit
data
show
three
inhibitor
prevent
syncytia
format
induc
ibv
indic
fewer
nuclei
per
syncytium
compar
infect
untreat
cell
decreas
nuclei
per
syncytium
ibv
sand
sarscov
sexpress
cell
treat
imatinib
demonstr
abl
kinas
inhibitor
prevent
syncytia
format
induc
protein
absenc
viral
protein
result
demonstr
fusion
inhibit
hemifus
step
prior
lipid
mix
membran
addit
show
cleavag
affect
imatinib
suggest
ibv
process
cleavag
independ
abl
kinas
activ
inhibit
specif
inhibitor
abl
kinas
strongli
suggest
ibv
infect
requir
activ
andor
previou
report
show
requir
entri
sarscov
merscov
involv
cell
signal
embryon
develop
cell
migrat
invas
cancer
distinct
domain
provid
abl
kinas
abil
act
scaffold
facilit
build
signal
complex
regul
protein
function
phosphoryl
downstream
protein
target
bind
actin
fabd
directli
regul
cytoskeleton
dynam
activ
essenti
cellular
pathway
describ
hypothes
coronaviru
infect
requir
multifunct
action
abl
kinas
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
viru
fusion
plasma
membran
endosom
membran
order
gain
entri
host
cell
like
viruscel
cellcel
fusion
induc
coronaviru
protein
use
similar
mechan
abl
kinas
activ
play
role
cytoskelet
rearrang
hypothes
abl
kinas
inhibitor
act
interf
actin
dynam
requir
viruscel
cellcel
fusion
hypothesi
support
two
front
first
cytoskelet
dynam
implic
infect
sever
virus
actin
cytoskeleton
rearrang
shown
requir
infect
coxsackieviru
vaccinia
viru
hiv
variola
monkeypox
studi
demonstr
cytoskelet
rearrang
common
mechan
requir
mani
cellular
process
hijack
virus
infect
review
other
second
abl
kinas
role
actin
cytoskelet
rearrang
requir
essenti
cellcel
fusion
event
includ
limit
osteoclast
myoblast
fusion
develop
actininduc
podosom
like
structur
requir
fusion
osteoclast
myoblast
presum
alter
membran
tension
interestingli
harmon
et
al
report
cellcel
fusion
mediat
hiv
envelop
protein
inhibit
imatinib
posthemifus
step
observ
increas
hemifus
event
treatment
ibvinfect
cell
imatinib
sinc
use
differ
viru
cell
line
fusion
assay
difficult
compar
two
result
favor
idea
viru
interact
host
cell
receptor
induc
actin
rearrang
abl
kinas
activ
bring
cell
membran
close
proxim
allow
hemifus
follow
full
fusion
result
demonstr
coronavirusmembran
fusion
step
block
abl
kinas
inhibitor
suggest
previou
report
result
also
indic
abl
kinas
activ
may
involv
membran
fusion
event
requir
infect
coronavirus
imatinib
potenti
gener
coronaviru
inhibitor
work
strongli
suggest
protein
involv
abl
kinas
pathway
excel
target
develop
treatment
coronaviru
infect
current
studi
underway
determin
abl
kinas
function
involv
coronaviru
infect
well
determin
whether
activ
kinas
requir
coronaviru
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
infect
given
role
abl
kinas
play
infect
mani
virus
make
pathway
prime
target
use
develop
broadli
act
antivir
therapeut
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
figur
legend
figur
ibv
infect
suppress
abl
kinas
inhibitor
vero
cell
pretreat
h
imatinib
cell
adsorb
h
ibv
moi
presenc
dmso
drug
supernat
harvest
use
plaqu
assay
determin
viral
titer
b
immunofluoresc
stain
ibv
protein
use
count
number
infect
cell
presenc
dmso
drug
cell
analyz
per
experiment
condit
three
independ
experi
cell
infect
calcul
compar
number
infect
cell
number
total
cell
analyz
error
bar
repres
standard
error
p
valu
calcul
use
pair
test
p
p
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
vero
cell
transfect
plasmid
encod
ibv
b
sarscov
c
dmso
imatinib
ad
medium
h
posttransfect
cell
examin
h
posttransfect
top
imag
show
indirect
immunofluoresc
assay
detect
ibv
sarscov
c
graph
show
quantif
nuclei
per
syncytium
ibv
b
sarscov
presenc
dmso
drug
b
syncytia
analyz
three
independ
experi
error
bar
repres
standard
deviat
p
valu
calcul
use
pair
test
p
p
